ABSTRACT
O Comitê de Integridade na Pesquisa do Instituto Adolfo Lutz (CIPIAL), com o objetivo de promover a cultura da integridade científica como um dos valores fundamentais defendidos pela instituição nas suas atividades de pesquisa, considera relevante compartilhar com a comunidade científica a sua implantação, destacando o seu papel no gerenciamento deste tema na instituição. Após a publicação de seu regimento, de acordo com as suas competências primordiais, o CIPIAL elaborou e publicou o Código de Boas Práticas Científicas do IAL com o objetivo de definir as políticas de integridade para orientar os profissionais envolvidos com a pesquisa. (AU)
The Research Integrity Committee of the Adolfo Lutz Institute (CIPIAL), with the aim of promoting the culture of scientific integrity as one of the fundamental values defended by the institution in its research activities, considers it relevant to share its implementation with the scientific community, highlighting its role in managing this issue at the institution. Following the publication of its rules and regulations, in accordance with its core competencies, CIPIAL drew up and published the IAL Code of Good Scientific Practice with the aim of defining integrity policies to guide professionals involved in research. (AU)
Subject(s)
Research Personnel , Scientific Misconduct , Scientific Integrity Review , Ethics, ResearchABSTRACT
ABSTRACT The COVID-19 pandemic in Brazil has been marked by high infection and death rates. The immune response generated by current vaccination might be influenced by previous natural infection, and baseline estimates may help in the evaluation of vaccine-induced serological response. We evaluated previous SARS-CoV-2 testing (RT-PCR), and performed rapid diagnostic tests (RDT) and high throughput electrochemiluminescence immunoassay (ECLIA) before vaccination among people living with HIV (PLWH), users of antiretroviral prophylaxis (PrEP/PEP), and healthcare professionals in an HIV outpatient clinic (HCP-HC). RDT was positive in 25.7% (95% CI: 19-33%) overall, 31.3% (95% CI : 18-45%) among PLWH, 23.7% (95% CI : 14-34%) in PrEP/PEP users and 21.4% (95% CI : 05-28%) in HCP-HC (p=0.548). Diagnostic RT-PCR testing was very limited, even for symptomatic individuals, and whereas all HCP-HC had one test perfomed, only 35% of the patients (PREP/PEP/PLWH) were tested (p<0.0001). Adequate monitoring of post-vaccination humoral response and breakthrough infections including those in asymptomatic cases are warranted, especially in immunologically compromised individuals.